DK0714912T3 - Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140 - Google Patents

Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140

Info

Publication number: DK0714912T3
Authority: DK; Denmark
Prior art keywords: gmp; alpha; sialyated; ligands; peptides
Prior art date: 1990-07-17

Application number

DK95202380T

Other languages

Danish (da)

English (en)

Inventor

Rodger P Mcever

Original Assignee

Univ Oklahoma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-17

Filing date

1991-07-17

Publication date

2003-02-03

1991-07-17 Application filed by Univ Oklahoma filed Critical Univ Oklahoma

2003-02-03 Application granted granted Critical

2003-02-03 Publication of DK0714912T3 publication Critical patent/DK0714912T3/da

Links

108010035766 P-Selectin Proteins 0.000 title abstract 4
102000008212 P-Selectin Human genes 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
108090000184 Selectins Proteins 0.000 title abstract 2
102000003800 Selectins Human genes 0.000 title abstract 2
239000003446 ligand Substances 0.000 title 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 title 1
150000001720 carbohydrates Chemical group 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
PNIWLNAGKUGXDO-LNCRCTFVSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PNIWLNAGKUGXDO-LNCRCTFVSA-N 0.000 abstract 1
102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 abstract 1
108010024212 E-Selectin Proteins 0.000 abstract 1
102000015689 E-Selectin Human genes 0.000 abstract 1
101000819503 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Proteins 0.000 abstract 1
101001022183 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5 Proteins 0.000 abstract 1
101001022175 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Proteins 0.000 abstract 1
101000862183 Homo sapiens Alpha-(1,3)-fucosyltransferase 10 Proteins 0.000 abstract 1
101000862213 Homo sapiens Alpha-(1,3)-fucosyltransferase 11 Proteins 0.000 abstract 1
101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 abstract 1
108010092694 L-Selectin Proteins 0.000 abstract 1
108090001090 Lectins Proteins 0.000 abstract 1
102000004856 Lectins Human genes 0.000 abstract 1
102000010836 Lymphocyte Homing Receptors Human genes 0.000 abstract 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 abstract 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
239000000370 acceptor Substances 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000002523 lectin Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000014508 negative regulation of coagulation Effects 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK95202380T 1990-07-17 1991-07-17 Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140 DK0714912T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55419990A	1990-07-17	1990-07-17
US65048491A	1991-02-05	1991-02-05

Publications (1)

Publication Number	Publication Date
DK0714912T3 true DK0714912T3 (da)	2003-02-03

Family

ID=27070521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95202380T DK0714912T3 (da)	1990-07-17	1991-07-17	Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140

Country Status (9)

Country	Link
EP (2)	EP0714912B1 (de)
JP (5)	JP3096305B2 (de)
AT (1)	ATE224911T1 (de)
AU (2)	AU660627B2 (de)
CA (1)	CA2086323C (de)
DE (1)	DE69133120T2 (de)
DK (1)	DK0714912T3 (de)
ES (1)	ES2183851T3 (de)
WO (1)	WO1992001718A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800815A (en) *	1903-05-05	1998-09-01	Cytel Corporation	Antibodies to P-selectin and their uses
US5464778A (en) *	1989-03-08	1995-11-07	Board Of Regents Of The University Of Oklahoma	Glycoprotein ligand for P-selectin and methods of use thereof
JPH05504470A (ja) *	1989-10-20	1993-07-15	ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド	Ｐａｄｇｅｍを介した細胞結合の阻害
US6387884B1 (en)	1990-06-18	2002-05-14	Stanford University	Leukocyte homing modulation
US6391857B1 (en)	1990-06-18	2002-05-21	Stanford University	Methods and compositions for endothelial binding
NZ240316A (en) *	1990-10-25	1996-12-20	Univ Michigan	Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
US6309639B1 (en)	1991-02-05	2001-10-30	The Board Of Regents Of The University Of Oklahoma	Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) *	1991-02-05	2000-09-26	Southpac Trust Internationals, Inc.	O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5807745A (en) *	1991-03-11	1998-09-15	New England Medical Center Hospitals, Inc.	Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en)	1991-04-19	2000-09-19	John L. Magnani	Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
ATE338762T1 (de) *	1991-04-19	2006-09-15	Univ Leland Stanford Junior	Zusammensetzungen und methoden für die verknüpfung von endothelzellen
AU667813B2 (en) *	1991-05-03	1996-04-18	Rockefeller University, The	Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions
AU2029392A (en) *	1991-05-14	1992-12-30	Board Of Regents Of The University Of Oklahoma, The	Peptide inhibitors of inflammation
US5646123A (en) *	1991-06-10	1997-07-08	Alberta Research Council	Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
CA2118695A1 (en) *	1991-09-10	1993-03-18	George A. Heavner	Peptide inhibitors of inflammation mediated by selectins
WO1993005803A1 (en) *	1991-09-25	1993-04-01	Genetics Institute, Inc.	Anti-inflammatory selectin inhibitors
EP0602194A1 (de) *	1991-12-18	1994-06-22	Centocor, Inc.	Peptid-inhibitoren von die durch selektine verursachten entzundungen
JPH07506253A (ja) *	1992-04-30	1995-07-13	ジェネンテク，インコーポレイテッド	セレクチン変異体
US6033667A (en) *	1992-05-05	2000-03-07	Cytel Corporation	Method for detecting the presence of P-selectin
DK0642356T3 (da) *	1992-05-05	2003-08-04	Aeres Biomedical Ltd	Antistoffer mod P-selectin og deres anvendelser
US5728802A (en) *	1992-05-06	1998-03-17	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) *	1992-05-06	1997-07-01	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) *	1992-05-06	1997-07-15	Affymax Technologies N.V.	Peptides and compounds that bind to ELAM-1
JPH07507302A (ja) *	1992-05-28	1995-08-10	セントコー・インコーポレーテッド	セレクチン結合のペプチド阻害剤
EP0652897A4 (de) *	1992-05-28	1995-09-20	Centocor Inc	Peptid inhibitoren gegen die selektinbindung.
US5440015A (en) *	1992-07-21	1995-08-08	Glycomed Incorporated	Selectin peptide medicaments for treating disease
CA2144180A1 (en) *	1992-09-08	1994-03-17	George A. Heavner	Peptide inhibitors of cellular adhesion
ATE210452T1 (de)	1992-10-02	2001-12-15	Alberta Res Council	Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
US6277975B1 (en)	1992-10-23	2001-08-21	Genetics Institute, Inc.	Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) *	1992-10-23	1998-12-01	Genetics Institute, Inc.	Nucleic acid encoding a novel P-selectin ligand protein
WO1994010309A1 (en) *	1992-10-23	1994-05-11	Genetics Institute, Inc.	Novel p-selectin ligand protein
AU681369B2 (en) *	1992-11-16	1997-08-28	Board Of Regents Of The University Of Oklahoma, The	Glycoprotein ligand for P-selectin and methods of use thereof
WO1994014836A1 (en) *	1992-12-18	1994-07-07	Centocor, Inc.	Peptide inhibitors of selectin binding
US5856300A (en) *	1994-05-12	1999-01-05	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) *	1993-05-17	1999-11-02	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
ATE215094T1 (de)	1993-05-17	2002-04-15	Avant Immunotherapeutics Inc	Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
US5750508A (en) *	1993-06-16	1998-05-12	Glycomed Incorporated	Sialic acid/fucose based medicaments
WO1995014787A1 (en) *	1993-11-22	1995-06-01	Centocor, Inc.	Peptide inhibitors of selecting binding
US5663151A (en) *	1994-03-04	1997-09-02	Bristol-Myers Squibb Company	Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2142153A1 (en) *	1994-03-04	1995-09-05	Jacques Banville	Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
WO1995030001A2 (en) *	1994-04-28	1995-11-09	Genetics Institute, Inc.	Novel p-selectin ligand protein
US5686426A (en) *	1994-11-17	1997-11-11	Bristol-Myers Squibb Company	Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
CZ401497A3 (cs) *	1995-06-14	1998-07-15	The General Hospital Corporation	P-selektinové ligandy a příbuzné molekuly a způsoby
US5747463A (en) *	1995-11-13	1998-05-05	Bristol-Myers Squibb Company	Malonate derivatives of glycolipids as cell adhesion inhibitors
NZ333250A (en)	1996-06-10	2000-05-26	Thomas Boren	Helicobacter pylori blood group antigen binding adhesion protein
MEP42108A (en)	1998-10-23	2011-02-10	Kiren Amgen Inc	Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
WO2003097658A2 (en)	2002-05-16	2003-11-27	Glycomimetics, Inc.	Compounds and methods for inhibiting selectin-mediated function
EP1763533B1 (de)	2003-11-19	2008-01-09	GlycoMimetics, Inc.	Spezifischer antagonist sowohl für e- als auch p-selektine
US8143380B2 (en)	2004-07-08	2012-03-27	Amgen Inc.	Therapeutic peptides
WO2006036834A2 (en)	2004-09-24	2006-04-06	Amgen Inc.	MODIFIED Fc MOLECULES
CN101291946B (zh)	2005-08-09	2011-06-29	糖模拟物有限公司	对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
PL2264043T3 (pl)	2005-09-02	2018-04-30	Glycomimetics, Inc.	Heterobifunkcyjne inhibitory pan-selektyny
WO2009126556A1 (en)	2008-04-08	2009-10-15	Glycomimetics, Inc.	Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en)	2010-09-14	2014-12-30	Glycomimetics, Inc.	E-selectin antagonists
KR102055958B1 (ko)	2011-12-22	2019-12-13	글리코미메틱스, 인크.	E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
US9867841B2 (en)	2012-12-07	2018-01-16	Glycomimetics, Inc.	Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
JP6689854B2 (ja)	2014-12-03	2020-04-28	グリコミメティクス，インコーポレイテッド	Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
JP2019502727A (ja)	2016-01-22	2019-01-31	グリコミメティクス，インコーポレイテッド	Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
WO2017151708A1 (en)	2016-03-02	2017-09-08	Glycomimetics, Inc.	Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en)	2016-08-08	2022-09-06	Glycomimetics, Inc.	Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
AU2017341065B2 (en)	2016-10-07	2023-04-06	Crescent Biopharma, Inc.	Highly potent multimeric E-selectin antagonists
KR20250159733A (ko)	2017-01-11	2025-11-11	브리스톨-마이어스 스큅 컴퍼니	Psgl-1 길항제 및 그의 용도
PE20250933A1 (es)	2017-03-14	2025-04-02	Five Prime Therapeutics Inc	Anticuerpos de union a vista a ph acido
EP3596096A1 (de)	2017-03-15	2020-01-22	GlycoMimetics, Inc.	Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
JP7275131B2 (ja)	2017-11-30	2023-05-17	グリコミメティクス，インコーポレイテッド	骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko)	2017-12-29	2020-09-04	글리코미메틱스, 인크.	E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR20200128025A (ko)	2018-03-05	2020-11-11	글리코미메틱스, 인크.	급성 골수성 백혈병 및 관련 병태의 치료 방법
BR112020019083A2 (pt)	2018-03-21	2020-12-29	Five Prime Therapeutics, Inc.	Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es)	2018-07-11	2021-04-08	Bristol Myers Squibb Co	Anticuerpos de union a vista a ph acido
US11845771B2 (en)	2018-12-27	2023-12-19	Glycomimetics, Inc.	Heterobifunctional inhibitors of E-selectin and galectin-3
EP4182700A4 (de) *	2020-07-20	2024-11-13	Insmed Incorporated	Verfahren zur extraktion neutrophiler serinproteasen und behandlung dipeptidylpeptidase-1-vermittelter erkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3625214A (en)	1970-05-18	1971-12-07	Alza Corp	Drug-delivery device
US4244946A (en)	1979-06-11	1981-01-13	The Salk Institute For Biological Studies	Water-soluble peptides affecting gonadal function
US4305872A (en)	1979-10-19	1981-12-15	Kenneth Wingrove	Polypeptide derivatives
US4316891A (en)	1980-06-14	1982-02-23	The Salk Institute For Biological Studies	Extended N-terminal somatostatin
US4792525A (en)	1982-08-04	1988-12-20	La Jolla Cancer Research Foundation	Tetrapeptide
US4906474A (en)	1983-03-22	1990-03-06	Massachusetts Institute Of Technology	Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en)	1983-08-16	1986-12-16	The University Of Georgia Research Foundation, Inc.	Synthesis of cyclopropane amino acids
US4752569A (en) *	1984-06-21	1988-06-21	The Regents Of The University Of California	Sialylated Lewisx epitope, antibodies and diagnosis
US4783330A (en) *	1984-11-15	1988-11-08	New England Medical Center Hospitals, Inc.	Monoclonal antibodies to activated platelets
US4789734A (en)	1985-08-06	1988-12-06	La Jolla Cancer Research Foundation	Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4904596A (en) *	1985-08-07	1990-02-27	Fred Hutchinson Cancer Research Center	Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
AU610083B2 (en)	1986-08-18	1991-05-16	Clinical Technologies Associates, Inc.	Delivery systems for pharmacological agents
US5030723A (en) *	1988-05-31	1991-07-09	The Biomembrane Institute	Long-chain glycolipid structure
JPH05504470A (ja) *	1989-10-20	1993-07-15	ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド	Ｐａｄｇｅｍを介した細胞結合の阻害

1991
- 1991-07-17 ES ES95202380T patent/ES2183851T3/es not_active Expired - Lifetime
- 1991-07-17 JP JP03517240A patent/JP3096305B2/ja not_active Expired - Fee Related
- 1991-07-17 AU AU86207/91A patent/AU660627B2/en not_active Ceased
- 1991-07-17 DK DK95202380T patent/DK0714912T3/da active
- 1991-07-17 EP EP95202380A patent/EP0714912B1/de not_active Expired - Lifetime
- 1991-07-17 DE DE69133120T patent/DE69133120T2/de not_active Expired - Fee Related
- 1991-07-17 AT AT95202380T patent/ATE224911T1/de not_active IP Right Cessation
- 1991-07-17 WO PCT/US1991/005059 patent/WO1992001718A2/en not_active Ceased
- 1991-07-17 EP EP19910916882 patent/EP0544815A1/de not_active Withdrawn
- 1991-07-17 CA CA002086323A patent/CA2086323C/en not_active Expired - Fee Related
1995
- 1995-04-28 AU AU17731/95A patent/AU697488B2/en not_active Ceased
1998
- 1998-08-03 JP JP10219500A patent/JPH11147900A/ja not_active Withdrawn
2000
- 2000-11-22 JP JP2000356784A patent/JP2001197899A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178744A patent/JP2004002444A/ja not_active Withdrawn
2005
- 2005-05-26 JP JP2005154747A patent/JP2005255691A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2001197899A (ja)	2001-07-24
ATE224911T1 (de)	2002-10-15
JPH11147900A (ja)	1999-06-02
EP0544815A1 (de)	1993-06-09
JP2004002444A (ja)	2004-01-08
AU1773195A (en)	1995-07-06
AU8620791A (en)	1992-02-18
CA2086323C (en)	2002-05-14
DE69133120T2 (de)	2003-05-15
EP0714912B1 (de)	2002-09-25
ES2183851T3 (es)	2003-04-01
JP3096305B2 (ja)	2000-10-10
AU697488B2 (en)	1998-10-08
DE69133120D1 (de)	2002-10-31
AU660627B2 (en)	1995-07-06
EP0714912A3 (de)	1996-06-26
EP0714912A2 (de)	1996-06-05
WO1992001718A3 (en)	1992-05-14
CA2086323A1 (en)	1992-01-18
JPH05509330A (ja)	1993-12-22
WO1992001718A2 (en)	1992-02-06
JP2005255691A (ja)	2005-09-22

Publication	Publication Date	Title
DK0714912T3 (da)	2003-02-03	Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140
Spiro et al.	1974	Structure of the O-glycosidically linked carbohydrate units of fetuin
Gabius	1997	Animal lectins
Florman et al.	1985	O-linked oligosaccharides of mouse egg ZP3 account for its sperm receptor activity
Cantoni et al.	1998	p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
Tanaka et al.	1964	Serine and threonine glycosidic linkages in bovine submaxillary mucin
Stamenkovic et al.	1991	The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2–6 sialyltransferase, CD75, on B cells
Labeta et al.	1993	Release from a human monocyte‐like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14
Chibnall et al.	1958	Studies on the amide and C-terminal residues in proteins. 2. The ammonia nitrogen and amide nitrogen of various native protein preparations
GB9923306D0 (en)	1999-12-08	Diagnostic and therapeutic epitope, and transgenic plant
Foltz et al.	1990	Purification and characterization of an extracellular fragment of the sea urchin egg receptor for sperm.
Matsumoto et al.	1982	Structural study of the sugar chains of human lactoferrin: finding of four novel complex-type asparagine-linked sugar chains
US4444757A (en)	1984-04-24	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
Childs et al.	1981	Differences in carbohydrate moieties of high molecular weight glycoproteins of human lymphocytes of T and B origins revealed by monoclonal autoantibodies with anti-I and anti-i specificities
Cahan et al.	1980	Polyorna virus adsorbs to specific sialyloligosaccharide receptors on erythrocytes
Dahms et al.	1985	Lymphocyte function-associated antigen 1 (LFA-1) contains sulfated N-linked oligosaccharides.
NO971621L (no)	1997-06-12	Keratinocyttvekstfaktoranaloger
Samor et al.	1982	Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf)
Hirabayashi	1993	A general comparison of two major families of animal lectins
Efremov et al.	1965	Differences in cattle globins
von dem Bruch et al.	1994	Synthesis of N‐Glycopeptide Clusters with Lewisx Antigen Side Chains and Their Coupling to Carrier Proteins
Åkerström et al.	1984	α1‐Microglobulin Glycopeptides Inhibit Antigen‐Specific Stimulation of Human Peripheral Blood Leucocytes
EP1245575A3 (de)	2002-11-20	Funktionell aktive selektinderivierte Peptide und Ligand für GMP140
Bell et al.	1977	Effect of galactose oxidase, with and without prior sialidase treatment, on the viability of erythrocytes in circulation.
WO2002022784A2 (en)	2002-03-21	Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g